Literature DB >> 11717336

Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma.

C Jerónimo1, H Usadel, R Henrique, J Oliveira, C Lopes, W G Nelson, D Sidransky.   

Abstract

BACKGROUND: Methylation of regulatory sequences near GSTP1, which encodes the pi class glutathione S-transferase, is the most common epigenetic alteration associated with prostate cancer. We determined whether the quantitation of GSTP1 methylation in histopathologically distinct prostate tissue samples could improve prostate cancer detection.
METHODS: We used a fluorogenic real-time methylation-specific polymerase chain reaction (MSP) assay to analyze cytidine methylation in the GSTP1 promoter in prostate tissue samples from 69 patients with early-stage prostatic adenocarcinoma (28 of whom also had prostatic intraepithelial neoplasia lesions) and 31 patients with benign prostatic hyperplasia. The relative level of methylated GSTP1 DNA in each sample was determined as the ratio of MSP-amplified GSTP1 to MYOD1, a reference gene. We also performed a prospective, blinded investigation to quantitate GSTP1 promoter methylation in sextant prostate biopsy specimens from 21 additional patients with elevated serum prostate-specific antigen levels, 11 of whom had histologically identified adenocarcinoma and 10 of whom had no morphologic evidence of adenocarcinoma. All data were analyzed by using nonparametric two-sided statistical tests.
RESULTS: The median ratios (and interquartile ranges) of MSP-amplified GSTP1 to MYOD1 in resected benign hyperplastic prostatic tissue, intraepithelial neoplasia, and adenocarcinoma were 0 (range, 0-0.1), 1.4 (range, 0- 45.9), and 250.8 (range, 53.5-697.5), respectively; all of these values were statistically significantly different (P< .001). The median ratios of MSP-amplified GSTP1 to MYOD1 in the prospectively collected sextant biopsy samples were 410.6 for the patients with adenocarcinoma and 0.0 for the patients with no evidence of adenocarcinoma (P< .001).
CONCLUSION: Quantitation of GSTP1 methylation accurately discriminates between normal hyperplastic tissue and prostatic carcinoma in small samples of prostate tissue and may augment the standard pathologic/histologic assessment of the prostate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11717336     DOI: 10.1093/jnci/93.22.1747

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  83 in total

1.  DAPK promoter hypermethylation in tissues and body fluids of oral precancer patients.

Authors:  Yang Liu; Zeng-Tong Zhou; Qing-Bo He; Wei-Wen Jiang
Journal:  Med Oncol       Date:  2011-04-24       Impact factor: 3.064

Review 2.  Promoter hypermethylation in prostate cancer.

Authors:  Jong Y Park
Journal:  Cancer Control       Date:  2010-10       Impact factor: 3.302

Review 3.  Polycyclic aromatic hydrocarbon-DNA adduct formation in prostate carcinogenesis.

Authors:  Benjamin A Rybicki; Nora L Nock; Adnan T Savera; Deliang Tang; Andrew Rundle
Journal:  Cancer Lett       Date:  2005-09-09       Impact factor: 8.679

4.  GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer.

Authors:  Leonel Maldonado; Mariana Brait; Myriam Loyo; Lauren Sullenberger; Kevin Wang; Sarah B Peskoe; Eli Rosenbaum; Roslyn Howard; Antoun Toubaji; Roula Albadine; George J Netto; Mohammad O Hoque; Elizabeth A Platz; David Sidransky
Journal:  J Urol       Date:  2014-04-21       Impact factor: 7.450

5.  Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation.

Authors:  Kiyomi O Toyooka; Shinichi Toyooka; Anirban Maitra; Qinghua Feng; Nancy C Kiviat; Alice Smith; John D Minna; Raheela Ashfaq; Adi F Gazdar
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 6.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12

7.  Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression.

Authors:  Mohammad Obaidul Hoque; Maria Prencipe; Maria Luana Poeta; Raffaela Barbano; Vanna Maria Valori; Massimiliano Copetti; Antonietta Pia Gallo; Mariana Brait; Evaristo Maiello; Adolfo Apicella; Raffaele Rossiello; Francesco Zito; Tommasi Stefania; Angelo Paradiso; Massimo Carella; Bruno Dallapiccola; Roberto Murgo; Illuminato Carosi; Michele Bisceglia; Vito Michele Fazio; David Sidransky; Paola Parrella
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-29       Impact factor: 4.254

8.  Novel diagnostic biomarkers for prostate cancer.

Authors:  Chikezie O Madu; Yi Lu
Journal:  J Cancer       Date:  2010-10-06       Impact factor: 4.207

9.  Prostate cancer epigenetics: a review on gene regulation.

Authors:  Lena Diaw; Karen Woodson; John W Gillespie
Journal:  Gene Regul Syst Bio       Date:  2007-12-11

10.  Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma.

Authors:  Barbara Seliger; Diana Handke; Elisabeth Schabel; Juergen Bukur; Rudolf Lichtenfels; Reinhard Dammann
Journal:  J Transl Med       Date:  2009-10-26       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.